Tech Company Financing Transactions
Ascidian Therapeutics Funding Round
Ascidian Therapeutics closed a $40 million Series A funding round on 11/8/2023. Backers included Apple Tree Partners.
Transaction Overview
Company Name
Announced On
11/8/2023
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Apple Tree Partners (Michael Ehlers)
Proceeds Purpose
The company intends to use the funds to advance its lead program, an RNA exon editor to halt the progression of Stargardt disease or other ABCA4 retinopathies, and additional programs in the pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
80 Guest St Fourth Fl
Boston, MA 02135
USA
Boston, MA 02135
USA
Phone
Undisclosed
Website
Email Address
Overview
Ascidians -- also known as sea squirts -- are ocean creatures and primordial ancestors of vertebrates. To grow from larvae to adults, ascidians re-engineer their transcriptome through RNA trans-splicing and alternative splicing. Ascidian Therapeutics was founded to rewrite RNA by editing and replacing human exons, inspired by this example.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Ehlers
Chief Executive Officer
Romesh Subramanian
Chief Financial Officer
Daniel Rosan
Chief Technical Officer
Jim Faulkner
Browse more venture capital transactions:
Prev: 11/8/2023: Ozone venture capital transaction
Next: 11/8/2023: MOGUL venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs